Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: BG00012 (DMF) (Tecfidera®.) Clear all
Completed No phase listed Observational

Tecfidera Lymphocyte Chart Review

NCT02519413
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Homewood, Alabama • Newport Beach, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 2, 2026, 2:31 AM EDT
Terminated Phase 4 Interventional Results available

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate

NCT02117050
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif®
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 2, 2026, 2:31 AM EDT
Terminated Phase 3 Interventional Results available

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

NCT02907177
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ponesimod, Placebo
Drug · Other
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
26
States / cities
Birmingham, Alabama • Fresno, California • Pasadena, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers

NCT02171208
View directory record Official record
Conditions
Healthy
Interventions
dimethyl fumarate - Reference form, dimethyl fumarate - Test form
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 9, 2015 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 4 Interventional Results available

Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera

NCT02410278
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dimethyl fumarate, montelukast, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
50
States / cities
Jonesboro, Arkansas • Carmichael, California • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily

NCT01915901
View directory record Official record
Conditions
Healthy
Interventions
bismuth subsalicylate (Pepto-Bismol®), matching placebo (bismuth subsalicylate), dimethyl fumarate (DMF)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers

NCT04022473
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Bafiertam, Tecfidera
Drug
Lead sponsor
Banner Life Sciences LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 2, 2026, 2:31 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients

NCT03092544
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Multiple Sclerosis Center of Northeastern New York
Other
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Latham, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

NCT02097849
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
dimethyl fumarate, tetanus diphtheria toxoids vaccine, 23-valent pneumococcal polysaccharide vaccine, meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent), non-pegylated interferon
Drug · Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Gilbert, Arizona • Thornton, Colorado • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 2, 2026, 2:31 AM EDT
Terminated Phase 3 Interventional Results available

Tecfidera Slow-Titration Study

NCT02428231
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Gilbert, Arizona • Phoenix, Arizona • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

NCT00451451
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
BG00012, Placebo, Glatiramer Acetate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
72
States / cities
Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 2, 2026, 2:31 AM EDT
Terminated Phase 4 Interventional Results available

Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.

NCT02343159
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dimethyl fumarate, Medication Event Monitoring System (MEMS), Adherence counseling
Drug · Device · Behavioral
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
29
States / cities
Homewood, Alabama • Pheonix, Arizona • Carlsbad, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 2, 2026, 2:31 AM EDT
Completed No phase listed Observational

Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT02776072
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
2,978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
38
States / cities
Homewood, Alabama • Gilbert, Arizona • Hanford, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Dimethyl Fumarate for Obstructive Sleep Apnea

NCT02438137
View directory record Official record
Conditions
Obstructive Sleep Apnea, OSA, Sleep Apnea
Interventions
Dimethyl fumarate, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults

NCT02201849
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Study Drug, Active Control, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 4 Interventional Results available

Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)

NCT02739542
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Tecfidera, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
11
States / cities
Los Angeles, California • Baltimore, Maryland • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis

NCT00420212
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
BG00012, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
39
States / cities
Gilbert, Arizona • Phoenix, Arizona • San Francisco, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers

NCT02683863
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BG00012 (DMF) (Tecfidera®.)
Drug
Lead sponsor
Multiple Sclerosis Center of Northeastern New York
Other
Eligibility
25 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Latham, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 2, 2026, 2:31 AM EDT
Completed No phase listed Observational

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

NCT02823951
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Rebif, Tecfidera
Drug
Lead sponsor
IMS HEALTH GmbH & Co. OHG
Industry
Eligibility
18 Years to 55 Years
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
22
States / cities
Birmingham, Alabama • Colorado Springs, Colorado • Savannah, Georgia + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 2, 2026, 2:31 AM EDT
Active, not recruiting No phase listed Observational

Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity)

NCT07757568
View directory record Official record
Conditions
Multiple Sclerosis (MS) Relapsing Remitting
Interventions
Vumerity, Tecfidera
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 2, 2026, 2:31 AM EDT
Completed No phase listed Observational

Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)

NCT02159573
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
natalizumab, dimethyl fumarate
Biological · Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
43
States / cities
Birmingham, Alabama • Cullman, Alabama • Gilbert, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Oct 2, 2026, 2:31 AM EDT